Company intelligence / Profile preview

Estetra SRL

Liège, Liege, Belgium

Ownership: Private
Development stage: Commercial

Overview

Estetra has developed products that have received FDA approval, including one approved on May 23, 2019, and another on September 28, 2005. They have ongoing Phase 3 trials for Estetrol for vasomotor symptoms and Drospirenone/Estetrol combination.

Therapeutic areas: Women's Health
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

estetrol + drospirenone

Commercial

Indications: Contraception, Dysmenorrhea

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Estetra SRL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estetra SRL.

Explore the full profile